BioNotebook: Allergan's first Restasis challenge, Exelixis offering, Celladon IPO, EnVivo Phase III
This article was originally published in Scrip
The much-anticipated battle to bring generic Restasis (cyclosporine) to market has begun: Actavis subsidiary Watson Laboratories filed an abbreviated new drug application (ANDA) challenging Allergan's recently issued formulation patent for the top-selling dry eye drug.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.